A Valuable Option for the Treatment of Respiratory Diseases: Review on the Clinical Evidence of the Ivy Leaves Dry Extract EA 575®

Authors
Christopher Lang, Patricia Röttger-Lüer, Christiane Staiger

Affiliation
Engelhard Arzneimittel GmbH & Co. KG, Niederdorfelden, Germany

Key words
Hedera helix
Araliaceae
ivy
clinical trial
non-interventional study
efficacy
safety

Abstract
Preparations from ivy leaves (Hederae helicis folium, Hedera helix L., Araliaceae) dry extracts are well established in the treatment of different respiratory diseases. Until today, the efficacy and safety of ivy leaf preparations has been demonstrated in a variety of controlled clinical studies and non-interventional studies. These results were nearly exclusively obtained using the commercial ivy leaves dry extract EA 575®. This paper will provide information on the clinical data obtained with this special extract, showing the importance of those preparations as a valuable therapeutic option for the treatment of acute and chronic respiratory diseases. Overall, 18 publications covering clinical trials and non-interventional studies of, in total, 65,383 patients suffering from acute as well as chronic respiratory diseases were included.

Introduction
Due to their broncholytic and secretolytic efficacy, preparations from ivy leaves (Hederae helicis folium, Hedera helix L., Araliaceae) are well established in the treatment of productive cough and may also be used for the adjuvant therapy of inflammatory bronchial diseases [1–3]. Among the different ingredients of ivy leaves, such as flavonoids, phenyl carboxylic acids, or essential oil, saponines are primarily responsible for these therapeutic effects [4–8]. In particular, the monodesmosidic α-hederin, which arises from the biodesmosidic hederacoside C, was discovered to mediate both secretolysis and bronchodilation by preventing the internalization of β2-adrenergic receptors on the surface of bronchial smooth muscle cells and alveolar type II cells. As a consequence, a higher number of β2-adrenergic receptors can be activated by the endogenous ligand adrenaline. The β2-adrenergic receptor binding and the formation of cAMP is increased. This results in an increased bronchodilation and secretion of surfactant [9–13]. Thus, H. helix represents a rare example of a pharmaceutically used plant with a clarified mechanism of action for one of its ingredients.

In order to guarantee a safe and potent herbal extract with high yield of active ingredients, it is crucial to find and use optimized production parameters. Furthermore, herbal extracts that were obtained by procedures using different conditions might differ in their composition of the ingredients and, thus, in their therapeutic efficacy, potency, and safety [14, 15]. As a consequence, clinical data obtained by using different ivy leaf extracts cannot be transferred to each other. As shown in a huge number of clinical trials and observational studies, ivy leaf preparations containing the extract EA 575® [DER 5–7.5: 1, extraction solvent: ethanol 30% (m/m)] combine this therapeutic efficacy and excellent tolerability due to a patented extraction procedure. This review will summarize the results of studies all using preparations of the ivy leaves dry extract EA 575® for the treatment of cough and inflammatory bronchial diseases starting from 1990.

As a source for the review, the Engelhard Arzneimittel GmbH & Co. KG database was searched for all publications covering clinical studies using EA 575® preparations starting from the year 1990. Overall, 18 publications (6 in English, 11 in German, 1 in Slovenian) covering clinical trials

* Dedicated to Professor Dr. Dr. h. c. mult. Adolf Nahrstedt on the occasion of his 75th birthday.
and non-interventional studies of, in total, 65,383 patients suffering from acute as well as chronic respiratory diseases were included (Tables 1 and 2).

**Table 1** Summary of controlled clinical trials with ivy leaves extract EA 575®.

<table>
<thead>
<tr>
<th>Author/year</th>
<th>DF</th>
<th>No./age</th>
<th>Indication</th>
<th>S</th>
<th>O</th>
<th>R</th>
<th>P</th>
<th>C</th>
<th>DB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer-Wegener 1993 [18]</td>
<td>Drops</td>
<td>99 25–70 y</td>
<td>Simple or chronic bronchitis</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gulyas 1999 (cited according to [4])</td>
<td>Syrup</td>
<td>20 9–15 y</td>
<td>Chronic obstructive bronchitis</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maidannik 2003 [19]</td>
<td>Syrup</td>
<td>72 7 m-15 y</td>
<td>Acute inflammatory diseases of the respiratory tract</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bolbot 2004 [20]</td>
<td>Syrup</td>
<td>50 2–10 y</td>
<td>Acute bronchitis (obstructive and non-obstructive)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mansfeld 1998 [21]</td>
<td>Drops</td>
<td>24 4–12 y</td>
<td>Bronchial asthma</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zeil 2014 [22]</td>
<td>Syrup</td>
<td>30 6–11 y</td>
<td>Bronchial asthma</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gulyas 1997 [23]</td>
<td>Syrup</td>
<td>25 10–15 y</td>
<td>Chronic obstructive pulmonary diseases</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mansfeld 1997 [24]</td>
<td>Drops Supp.</td>
<td>26 5–11 y</td>
<td>Bronchial asthma</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unkauf 2000 [25]</td>
<td>Syrup</td>
<td>52 0–12 y</td>
<td>Bronchitis</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cwientzek 2011 [26]</td>
<td>Drops</td>
<td>590 2–86 y</td>
<td>Acute bronchitis</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DF: dosage form; Supp.: suppositories; S: subjective parameters assessed; O: objective parameters assessed; R: randomized; P: placebo-controlled; C: study with comparator; DB: double-blind; Comparators: 1ambroxol, 2acetylcystein, 3Valverde®, 4Hedelix®

**Table 2** Summary of observational trials with ivy leaves extract EA 575®.

<table>
<thead>
<tr>
<th>Author/year</th>
<th>DF</th>
<th>No./age</th>
<th>Indication</th>
<th>S</th>
<th>O</th>
<th>E</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gulyas 1992 [27]</td>
<td>Syrup</td>
<td>26 4–10 y</td>
<td>Chronic-obstructive bronchitis</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Lässig 1996 [28]</td>
<td>Syrup</td>
<td>113 6–15 y</td>
<td>Recurrent obstructive bronchitis</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Hecker 1999 [29]</td>
<td>Syrup Effervescent Tablet</td>
<td>248 0–79 y</td>
<td>Inflammatory and/or obstructive diseases of the respiratory tract</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Hecker 2002 [30]</td>
<td>Effervescent Tablet</td>
<td>1350 4–98 y</td>
<td>Chronic bronchitis</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Kraft 2004 [31]</td>
<td>Syrup</td>
<td>52 0–12 y</td>
<td>Symptomatic respiratory tract diseases</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Fazio 2009 [32]</td>
<td>Syrup</td>
<td>9657 0–98 y</td>
<td>Acute or chronic inflammatory bronchial diseases</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Stauss-Grabo 2011 [33]</td>
<td>Tablet</td>
<td>330 11–85 y</td>
<td>Colds accompanied by coughing/chronic inflam. bronchial disease</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Beden 2011 [34]</td>
<td>Syrup</td>
<td>193 2–14 y</td>
<td>Acute airway disease</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
</tbody>
</table>

DF: dosage form; S: subjective parameters assessed; O: objective parameters assessed; E: evaluation of efficacy; T: evaluation of tolerability

Lung Function Parameters

In the following, both spirometric and bodyplethysmographic parameters assessed in the studies will briefly be defined.

**Spirometric parameters [16]**

Spirometry is a fast and noninvasive method for the measurement of lung volume and respiratory flow parameters. It is applied for the diagnosis of diminished lung volume or an airway obstruction and its partial or full reversibility. VC (vital capacity): volume of air that is breathed out after complete inspiration. FVC (forced vital capacity): volume that is forcibly exhaled after complete inspiration. FEV1 (forced expiratory volume in 1 second): breathing volume that is forcibly exhaled in the first second after complete inspiration. MEFx% (maximal expiratory flow): maximal expiratory flow when x% of the FVC remain. MEFx%–x%: mean of the expiratory flow during the interval of x% to x% of the FVC. PEF (peak flow): peak flow during maximum expiratory effort.

**Bodyplethysmographic parameters [17]**

In contrast to spirometry, the degree of airway obstruction in body plethysmography is not assessed indirectly by the measurement of restrictions of the airflow during forced expiration but...
directly by measuring the airway resistance during tidal breathing. The setup of the body plethysmograph allows an objective measurement of the parameters that is less dependent on the patient's cooperativeness and the motivation by the instructor. RAW (airway resistance): airflow resistance of the respiratory tract during inspiration and expiration. sRAW (specific airway resistance): sRAW = RAW * ITGV. ITGV (intrathoracic gas volume): volume of air that is present in the lungs at the end of a passive expiration. RV (residual volume): volume of air that is present in the lungs after maximal forced expiration.

Controlled Clinical Studies

EA 575® ivy extract preparations vs. chemical expectorants with a different mechanism of action
In a randomized, controlled, double-blind study, the effect of Prospan® drops was examined in 99 adult patients (age 25–70 years) with simple or chronic bronchitis and compared with an ambroxol tablet preparation [18]. The patients were treated for four weeks either 3–5 times daily with 20 drops of the ivy leaves preparation or 3–5 times daily with an ambroxol 30 mg tablet including parallel administration of the respective placebo formulation (drops or tablets). The assessment was based on spirometric data (VC, FEV1, PEF), auscultatory findings, and subjective parameters (patient's diary). Both, ivy leaves extract drops and ambroxol tablets showed an equivalent therapeutic effect as documented by the improvement of objective and subjective parameters. The results indicate that patients with simple and chronic bronchitis and patients with obstructive chronic bronchitis may benefit from the ivy preparation comparatively to the secretolytic therapy with ambroxol [4]. The tolerance of both preparations was good to excellent. The additional bronchospasmolytic effect of the EA 575® formulation compared to ambroxol is depicted in a marked difference in the vital capacity in favor of the ivy group at the end of the treatment (mean: + 9.5% vs. + 1%). With respect to subjective parameters, the ivy leaves group did not suffer from dyspnea after four weeks anymore, whereas in the ambroxol group, the number of patients with dyspnea increased. Additionally, the antitussive effect tended to be stronger in the ivy leaves group. This study indicates that the ivy leaves dry extract is not inferior to the synthetic mucolytic ambroxol and, furthermore, exerts broncholytic properties.

In 1999, the effect of an EA 575® preparation was compared with acetylcysteine (ACC) in the treatment of 20 inpatients (9–15 years) suffering from chronic obstructive bronchitis (Gulyas et al. 1999, cited according to [4]). The patients were treated for 14–20 days with the ivy leaves preparation (n = 10) or ACC (n = 10). The assessment of the efficacy of the therapy by measurement of spirometric and body plethysmographic parameters revealed improvement of VC, FEV1, PEF, and RAW with marked advantages in favor of the ivy group.

In a similar open and controlled study, the effect of an EA 575®-containing syrup (n = 53) and ambroxol syrup (n = 19) was compared in the treatment of 72 children (7 months–15 years) suffering from acute inflammatory diseases of the respiratory tract [19]. The ivy leaves syrup was used in the following dosages: 1–6 years old (1 teaspoon 3 times daily), 7–14 years old (2 teaspoons 3 times daily). The treatment was carried out for 7–14 days, depending on the severity of the disease. The assessment of the efficacy was carried out using objective (VC, FVC, FEV1, PEF, MEF25, MEF50) and subjective (patient’s diaries) parameters before the beginning and during the medication period. The authors state that after seven days, auscultatory investigations revealed a fast decrease of crepitation only in the ivy group. Both treatments showed comparative results in the reduction of productive cough (after 7 days, >50% of the patients were healed; after 14 days: 100%). After seven days, children suffering from obstructive diseases showed a normalization of the velocity parameters of external respiration only in the ivy group. The potency of the therapy with the ivy leaves extract was rated as “excellent” or “good” in 90% (physicians) and 87.1% (patients) of the cases. This study supports the results conducted by Meyer-Weine et al. [18] and shows that patients with cough/viscous sputum may benefit from the use of an ivy preparation or ambroxol. Furthermore, the study demonstrated a positive influence on symptoms, such as cough, in acute inflammatory diseases. Blood analyses were performed, so the study contributes to safety data of high dosages of ivy leaf preparations in children [4].

In 2004, Prospan® cough syrup was compared with ACC in the treatment of 50 children (2–10 years) suffering from acute bronchitis (obstructive and nonobstructive) in an open and controlled study [20]. The ivy leaves group (n = 25) was dosed 3 times daily with 5 mL (2–6 years) or 3 times daily with 10 mL (7–10 years). The ACC group (n = 25) was dosed 3 times daily with 100–200 mg (2–6 years) or 3 times daily with 300–400 mg (7–10 years). Both groups were treated for 7–10 days. For evaluation, lung function parameters (FVC, FEV1, PEF, MEF25, MEF50, MEF75) and clinical symptoms were assessed. Both preparations showed equal expectorating action, but patients in the ivy group profited from a statistically significant higher improvement of the lung function parameters compared to the ACC group (e.g., ivy: FEV1 62 ± 8.4 to 129.62 ± 18.4; ACC: FEV1 63.7 ± 6.9 to 88.6 ± 8.5, values in % from normal), showing that the ivy leaves dry extract EA 575® exerts an obvious broncholytic action. Additionally, in 96% of cases, the efficacy (ACC: 79.2%) and in 100% of the cases, the tolerability (ACC: 76.2%) of the ivy leaves preparation was rated at least as “good”. The results of the study indicate that the ivy preparation has a benefit for secretolytic therapy in acute bronchitis, concomitant with a disturbance in the formation and transport of viscus expectoration. The comparison suggests that ivy extracts can be therapeutically equivalent or better than ACC in secretolytic therapy and improvement of cough in patients with acute bronchitis [4].

Placebo-controlled studies
In order to show the effect of ivy leaf preparations on the improvement of ventilatory disorders, the use of ivy leaves dry extract-containing drops in the treatment of 24 children (4–12 years) with bronchial asthma was evaluated in a randomized, double-blind, placebo-controlled, crossover study [21]. Patients were treated 2 times daily with 25 drops containing EA 575® or placebo over a period of three days each, interrupted by a wash-out phase of three to five days. The primary endpoint of the study was the change in RAW in comparison with placebo therapy. Besides RAW, other objective (ITGV, RV, VC, FVC, FEV1) and subjective (intensity of dyspnea, description of cough) parameters were measured. During active therapy, a clinically relevant and statistically significant decrease of the airways resistance (−0.14 kPa/l/s, −23.6%, p = 0.0361) and ITGV (−0.16 l, −10.1%, p = 0.0007) vs. placebo could be observed. Other spirometric parameters showed a clinically significant improvement in the ivy group compared to placebo. Mean increases in FEV1 found after inhalation of a β2-sympathomimetic, on day 3 of the treatment,
were conducted. Additionally, the patients filled out question- 
naire and documented peak flow and asthma symptoms. After the 
administration of the ivy leaves syrup, a partial improvement 
of lung function (MFE_{25-25} change in the mean 0.115 l/s, 
p = 0.044; MFE_{25} change in the mean 0.086 l/s, p = 0.041; VC, 
change in the mean 0.052 l, p = 0.044) compared to the placebo 
was demonstrated. Concerning the primary endpoint of the 
study (FEV_{1}), no significant change was observed, which might 
be due to the fact that children diagnosed with bronchial asthma 
often meet the clinical criteria for severe asthma despite having a 
normal or only slightly decreased FEV_{1}. The authors state that the 
MFE_{25-25} might therefore be regarded as the most significant pa-
rameter for airway obstruction and concluded that this proof-of-
concept study demonstrates a significant improvement in lung 
function parameters in children with mild, persistent, un-
trolled asthma by an add-on treatment with the ivy leaves dry 
extract EA 575°.

Further comparative studies

The potency of two different EA 575° dosage forms (ethanol-free 
syrup, 3 times with 5 mL per day; ethanol-containing drops, 3 
times with 20 drops per day) was compared in a randomized, 
double-blind, placebo-controlled, randomized, crossover study [22]. 
After the children were adjusted to 400 µg budesonide equiva-
 lent/day at the beginning of the run-in phase, the patients were 
treated 2 times daily with 5 mL dried ivy leaves syrup or placebo 
for 28–30 days each, interrupted by a washout phase of an addi-
tional 28–30 days. For evaluation of the therapy, spirometry and 
body plethysmography (e.g., FEV_{1}, MFE_{25-25}, MFE_{25}, VC, RAW) 
were conducted. Additionally, the patients filled out question-
naires and documented peak flow and asthma symptoms. After the 
administration of the ivy leaves syrup, a partial improvement 
of lung function (MFE_{25-25} change in the mean 0.115 l/s, 
p = 0.044; MFE_{25} change in the mean 0.086 l/s, p = 0.041; VC, 
change in the mean 0.052 l, p = 0.044) compared to the placebo 
was demonstrated. Concerning the primary endpoint of the 
study (FEV_{1}), no significant change was observed, which might 
be due to the fact that children diagnosed with bronchial asthma 
often meet the clinical criteria for severe asthma despite having a 
normal or only slightly decreased FEV_{1}. The authors state that the 
MFE_{25-25} might therefore be regarded as the most significant pa-
rameter for airway obstruction and concluded that this proof-of-
concept study demonstrates a significant improvement in lung 
function parameters in children with mild, persistent, un-
trolled asthma by an add-on treatment with the ivy leaves dry 
extract EA 575°.

Non-interventional studies

In a single center clinical test, 26 children (age 4–10 years) suffer-
ing from chronic obstructive bronchitis were treated with EA 
575°-containing syrup (4 times with 1–2 teaspoons per day) for 
four weeks [27]. The assessment of the efficacy of the therapy 
was carried out by weekly spirometric tests (e.g., VC, FVC, FEV_{1}, 
PFE) and auscultatory findings. Furthermore, the patients were 
asked to note dyspnea, frequency of coughing attacks, and expec-
toration in a patient diary. The symptoms alleviated rapidly and 
were either completely absent or present in an extremely mild 
form after conclusion of the therapy (e.g., statistically significant 
reduction of coughing frequency, p < 0.01). Supporting the allevi-
ation of the subjective parameters, significant improvements in 
all measured spirometric parameters were already identified 
after one week and auscultation identified significant differences
In dry rale between the start and the end of the study. The tolerance of the therapy was assessed as excellent in 92.3% of cases. In a multicenter surveillance study, the efficacy and safety of an ivy leaves syrup was investigated in the treatment of 113 children (6–15 years) suffering from recurrent obstructive bronchitis [28]. Over a period of up to 20 days (in some cases up to 30 days), 3 times with 5 mL syrup were administered daily to 64% of the children, whereas 32% got a higher (20–25 mL) and 4% a lower (7.5–10 mL) daily dose. The evaluation was based on spirometric (FVC, FEV1, PEF, MEF25, MEF50) and symptomatic (interview by physicians, patient’s diaries) parameters. After the treatment, the lung function of the patients significantly improved (e.g., FEV1: +0.167 l). Additionally, physicians confirmed a significant decrease in the quantity of cough and rated 85.7% of the patients as “healed” or “significantly improved”. The medication tolerability was rated as “very good” or “good” in 98.2% of the cases.

The efficacy and tolerability of EA 575®-containing syrup and effervescent tablets was assessed in two further open comparative multicentrically designed post-marketing observation trials [29]. Altogether 248 patients (0–79 years) suffering from inflammatory and/or obstructive diseases of the respiratory tract were treated with syrup (7.3 ± 2.4 days) or effervescent tablets (8.2 ± 2.5 days). 76% of the patients were treated following the recommended dosing in the patient information leaflet, 12% were treated with a higher, and 12% with a lower dose as recommended. The efficacy of the therapy was assessed by a doctor in a 4-level scale and by the patient judging the improvements of individual symptoms. The evaluation of tolerance resulted from the occurrence of adverse effects and from a general assessment made by the doctor. The efficacy of the therapy was rated as “very good” to “good” by the physicians in 86% of the cases. With regard to the individual symptoms, cough and expectoration had improved in 90% of the cases, and dyspnea and respiratory pain disappeared in 60% of the cases. Besides the excellent efficacy, the therapy tolerability was rated as “very good” to “good” by 98% of the patients. The results of the study demonstrate that the different dosages of the various administration forms of EA 575® established in clinical trials are also valid in wide clinical practice.

EA 575®-containing effervescent tablets were evaluated regarding their efficacy and tolerability in an additional multicenter post-marketing surveillance study by treating 1350 patients (4–98 years) suffering from chronic bronchitis [30]. The patients were treated according to the recommended dosing in the patient information leaflet for four weeks. During baseline examination, the symptoms of the bronchial illness and their duration were documented using a standardized questionnaire. At the end of the observational period, the physicians assessed the effectiveness and the tolerability of the treatment. Additionally, the patients were asked to describe any occurring adverse effects. After four weeks, more than 80% of the patients showed improved symptoms (cough 92.2%, expectoration 94.2%, dyspnea 83.1%, respiratory pain 86.9%) and were free of complaints in each of the four symptoms in 38% of the cases. Only three (0.2%) of the patients experienced adverse events in which a causal relationship to the drug under investigation could not be excluded.

The high level of tolerability of the EA 575®-containing syrup preparation was confirmed in a retrospective survey [31]. In the study, the type and frequency of adverse drug reactions of 52478 children (0–12 years) with symptomatic respiratory tract diseases, who were treated with ivy leaves syrup, were evaluated by the use of structured questionnaires. As a result, adverse drug reactions (ADR) occurred in only 0.22% (115) of all patients, which were all non-serious, mild, and transient in nature. The incidence of ADR’s decreased with increasing age. Furthermore, the most frequently mentioned ADR was diarrhea, which, in most cases, presumably results due to the sorbitol content of the cough syrup. The study provides substantial information on tolerance and safety because it included a large number of patients [4].

The tolerance, safety, and efficacy of H. helix extract was evaluated in a prospective post-marketing study with a large patient collective (n = 9657, 0–98 years, 53.7% children) suffering from acute or chronic inflammatory bronchial diseases [32]. The patients were treated with ivy leaves syrup (0–5 years: 3 times with 2.5 mL; 6–12 years: 3 times with 5 mL; > 12 years: 3 times with 5–7.5 mL per day) for seven days. Afterwards, the severity of the symptoms was compared with the initial examination, and the tolerability of the therapy was assessed by the physicians with a semi-closed questionnaire. In 95.1% of the cases, the symptoms (cough, expectoration, dyspnea, respiratory chest pain) were improved or completely absent. The tolerability of the therapy was rated as “good” or “very good” in 96.6% of the cases. Adverse events were only reported in a total of 2.1% of the patients, mostly reported in children mainly as mild or transient gastrointestinal disorders. The additional treatment with antibiotics might contribute to the increased rate of ADR’s compared to other studies, as the occurrence of gastrointestinal side effects during therapy with antibiotics is often observed. Therefore, it is most likely that the gastrointestinal side effects are primarily caused by the antibiotic treatment. The study provides substantial information on tolerance and safety because of the large number of patients and the use of relatively high dosages [4].

The tolerability of the ivy leaves dry extract in tablet form was evaluated in a post-marketing surveillance study by the treatment of 330 patients (11–85 years) suffering from colds accompanied by coughing or from chronic inflammatory bronchial diseases [33]. The patients received at least a seven-day treatment with a dose of 3 times 1 to 3 times 2 tablets per day. The tolerability was assessed by both practitioners and patients using questionnaires, whereas the compliance was evaluated only by the physicians. The excellent tolerability of the ivy leaves preparation could again be confirmed, as 98.5% of the practitioners and 96.4% of the patients judged the treatment as “very good” or “good” (no serious ADR was reported). Furthermore, the physicians rated the compliance of the tablet formulation as “good” in 99.1% of the cases.

In a prospective post-marketing study, 193 children (2–14 years) suffering from acute airway disease were treated with a H. helix extract-containing syrup [34]. The characteristics of individual symptoms (cough, expectoration, dyspnea, pain associated with cough) were evaluated before and seven days after treatment. The tolerability was documented by evaluation of all undesirable effects. After therapeutic intervention, 93.7% of the children experienced full or partial improvement of the symptoms (e.g., productive cough: 43.6% at first visit, 84.9% after seven days, significantly decreased nocturnal cough and frequency of cough). Furthermore, physicians and patients assessed the treatment of the symptoms with ivy leaves extract to be superior compared to treatment with other therapies in the past. The safety of the therapy with ivy leaf extracts was again confirmed, as 97.8% of the patients assessed the tolerance as “good” or “very good”.

Conclusion

Since decades, ivy leaves extract preparations have been used for the treatment of coughs, particularly when associated with hypersecretion of viscous mucus and as an adjunctive treatment of inflammatory bronchiolar diseases [3, 6, 35, 36]. Ivy leaves are a very good example of a well established and thoroughly investigated source of a phytopharmaceutical that is highlighted by the rare fact that the mechanism of action was clarified for parts of its active ingredients. Recently, it was shown that α-hederin, arising from the main saponine hedercoside C, prevents β2-adrenergic receptors from internalization and enables a higher number of receptors to be activated by the endogenous ligand adrenaline [11]. As a consequence, a higher grade of bronchodilation and surfactant production is achieved, leading to the bronchospasmolytic, secretolytic, expectorant and, in turn, antitussive effect of ivy leaves extract preparations, which were observed in clinical trials. Because of the well-established efficacy and tolerability, ivy leaves are listed in the ESCOP monography and in the positive list of the German Kommission E. Furthermore, the Committee on Herbal Medicinal Products (HMPC) attested certain ivy leaf extracts to fulfill the requirements of a well-established use with recognized efficacy [4, 5]. Among those, the ivy leaves dry extract EA 575® [DER: 5–7.5: 1, extraction solvent: ethanol 30% (m/m)], produced by a patented procedure, has a special status, as by far the most controlled clinical and post-marketing studies were carried out using this particular extract for treatment. These studies cover the huge number of, overall, more than 65,000 patients proving the efficacy and excellent tolerability of herbal medicinal products containing EA 575® as the active ingredient. The safety of these products is furthermore underlined by the fact that some of the studies included the application of higher dosages or the treatment of special population groups like children below 1 year of age. Despite the existing data of a very extensive patient collective, clinical research with preparations containing EA 575® has been performed further on. This is illustrated by the publication of four new studies [22, 26, 33, 34] since the release of the HMPC assessment report [4]. All of these studies further confirm the so far obtained findings regarding efficacy and safety of the ivy leaves dry extract. Furthermore, the non-inferiority of the ivy leaves extract in the treatment of respiratory tract illnesses compared to synthetic pharmaceuticals like ambroxol [18, 19] and acetylcysteine [20] could clearly be shown. Additionally, the patients treated with the ivy leaves extract benefit from the additional bronchospasmolytic effect, which enables the use in the adjunctive therapy of obstructive respiratory diseases like asthma bronchiale [21, 22, 24]. The results obtained for EA 575® from the clinical studies mentioned in this review apply exclusively for herbal medicinal products containing this extract, as extracts that are obtained by different procedures represent distinct active ingredients [37].

Conflict of Interest

Christopher Lang, Patricia Röttger-Lüer, and Christiane Staiger are employees of the Engelhard Arzneimittel GmbH & Co. KG.

References

22 Zell S, Schwanbeck U, Vogelberg C. Tolerance and effect of an add-on treatment with a cough medicine containing ivy leaves dry extract on lung function in children with bronchial asthma. Phytomedicine 2014; 21: 1216–1220
37 Veit M. Gleiche Quelle, gleiche Wirkung? Dtsch Apoth Ztg 2014; 33: 3518–3523